1. Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ 2020; 192(31): 875–891, doi: 10.1503/cmaj.191707.
2.
Nastanova 00500. Obesity treatment guideline DUODECIM MedicalPublications, Ltd. 2017 [cited 30.03.2023]. Available from URL: https://guidelines.moz.gov.ua/documents/3336.
3.
Obesity Canada published First Update to 2020 Adult Clinical Practice Guidelines: press release. 2022 Oct 21 [cited 30.03.2023]. Available from URL: https://obesitycanada.ca/.
4.
North American Association for the Study of Obesity National Heart Lung and Blood Institute National Institutes of Health (U.S.) NHLBI Obesity Education Initiative. The Practical Guide: Identification Evaluation and Treatment of Overweight and Obesity in Adults. Bethesda Md: National Institutes of Health National Heart Lung and Blood Institute NHLBI Obesity Education Initiative North American Association for the Study of Obesity [serial online]. 2000 Oct [cited 30.03.2023]. Available from URL: https://www.nhlbi.nih.gov/files/docs/guidelines/prctgd_c.pdf.
5.
Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Obes Facts 2016; 9(1): 642015, doi: 10.1159/000442721.
6.
Mayer SB, Graybill S, Raffa SD, et al. Synopsis of the 2020 U.S. VA/DoD Clinical Practice Guideline for the Management of Adult Overweight and Obesity. Mil Med 2021; 186(9–10): 884–896, doi: 10.1093/milmed/usab114.
7.
Obesity: identification, assessment and management Clinical guideline [CG189]. Published: 27 November 2014. [serial online] 2022 September 08 [cited 30.03.2023]. Available from URL: https://www.nice.org.uk/guidance/cg189/chapter/Recommendations#pharmacological-interventions.
8.
Call for authors – Special issue: Interventions for the treatment of persons with obesity Deadline of submission [serial online] 17 June 2022 [cited 30.03.2023]. Available from URL: https://www.who.int/news-room/articles-detail/call-for-authors-special-issue-interventions-for-the-treatment-of-persons-with-obesity.
9.
Sobczak K, Leoniuk K. Attitude towards obesity and its treatment – analysis of the attitudes of patients with obesit. Fam Med Prim Care Rev 2020; 22(4): 325–330, doi: 10.5114/fmpcr.2020.100443.
10.
Weight Loss Agents. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases [serial online] 2020 June [cited 30.03.2023]. Avail-able from URL: https://pubmed.ncbi.nlm.nih.gov/31644235/.
11.
Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes 2011; 36(6): 843–854, doi: 10.1038/ijo.2011.158.
12.
Raatz S, Gross AC. Clinical Assessment and Treatment of Early-Onset Severe Obesity. Curr Obes Rep 2021; 10(1): 31–38, doi: 10.1007/s13679-020-00418-6.
13.
National clinical evidence based guideline «Obesity in adults» [serial online] 2023 March [cited 30.03.2023]. Available from URL: https://www.dec.gov.ua/mtd/ozhyrinnya-u-doroslyh/.
14.
Website of FDA. Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000TOC.cfm
15.
Pedersen SD, Manjoo P, Wharton S. Canadian Adult Obesity Clinical Practice Guidelines: Pharmacotherapy for Obesity Management. Adult Obesity Clinical Practice Guidelines are a living document, with only the latest chapters posted at obesitycanada.ca/guidelines. Update History Version 2 [serial online] 2022 October 21 [cited 30.03.2023]. Avail-able from URL: https://obesitycanada.ca/guidelines/pharmacotherapy.
16.
Bray GA, Frühbeck G, Ryan DH, et al. Management of obesity. Lancet 2016; 387(10031): 1947–1956, doi: 10.1016/S0140-6736(16)00271-3.
17.
Gadde KM, Martin CK, Berthoud HR, et al. Obesity: Pathophysiology and Management. J Am Coll Cardiol 2018; 71(1): 69–84, doi: 10.1016/j.jacc.2017.11.011.
18.
Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352(9123): 167–172, doi: 10.1016/s0140-6736(97)11509-4.
19.
Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20(3): 270–279, doi: 10.1592/phco.20.4.270.34882.
20.
Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL – Primary Health Care Trial. Diabetes Obes Metab 2005; 7(1): 21–27, doi: 10.1111/j.1463-1326.2004.00428.x.
21.
Zhou YH, Ma XQ, Wu C, et al. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE 2012; 7(6): e39062, doi: 10.1371/journal.pone.0039062.
22.
Tkachenko V, Bagro T. Quality of life, mental health and sleep disorders in obese people of working age. West Kazakhstan Medical Journal 2021; 63(3): 152–157, doi: 10.24412/2707-6180-2021-63-145-151.
23.
Chapman JL, Cayanan EA, Hoyos CM, et al. Does Armodafinil Improve Driving Task Performance and Weight Loss in Sleep Apnea? A Randomized Trial. Am J Respir Crit Care Med 2018; 198(7): 941–950, doi: 10.1164/rccm.201712-2439OC.
24.
Auger RR, Burgess HJ, Emens JS, et al. Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2015; 11(10): 1199–1236, doi: 10.5664/jcsm.5100.
25.
Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999; 39(3): 281–288.
26.
Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999; 39(1): 30–40, doi: 10.1177/00912709922007534.
27.
Ferraro L, Fuxe K, Tanganelli S, et al. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J Neurosci Res 2002; 68(1): 107–112, doi: 10.1002/jnr.10196.
28.
Mitchell HA, Bogenpohl JW, Liles LC, et al. Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action. Pharmacol Biochem Behav 2008; 91(2): 217–222, doi: 10.1016/j.pbb.2008.07.014.
29.
Qu WM, Huang ZL, Xu XH, et al. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci 2008; 28(34): 8462–8469, doi: 10.1523/JNEUROSCI.1819-08.2008.
30.
Darwish M, Kirby M, Hellriegel ET, et al. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. Clin Drug Investig 2009; 29(2): 87–100, doi: 10.2165/0044011-200929020-00003.
31.
Food and Drug Administration. FDA-approved Labeling Text for NDA 21-875/NUVIGIL™ (armodafinil) Tablets. [serial online] 2007 June 15. Available from URL: http://www.accessdata.fda.gov.
32.
Beck P, Odle A, Wallace-Huitt T, et al. Modafinil increases arousal determined by P13 potential amplitude: an effect blocked by gap junction antagonists. Sleep 2008; 31(12): 1647–1654, doi: 10.1093/sleep/31.12.1647.
33.
Darwish M, Kirby M, Hellriegel ET, et al. Armodafinil and modafinil have substantially different pharmacokinetic pro-files despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig 2009; 29(9): 613–623, doi: 10.2165/11315280-000000000-00000.
34.
Ministry of Health Protection of Ukraine. Pharmaceutical Management State Expert Center of the Ministry of Health of Ukraine. State Register of Medicinal Products of Ukraine. Available from URL: http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlz1?opendocument&stype = 7AB171087377F824C22586D30038838B.
35.
Mavanji V, Pomonis B, Kotz CM. Orexin, serotonin, and energy balance. WIREs Mech Dis 2022; 14(1): e1536, doi: 10.1002/wsbm.1536.
36.
D’Ettorre G, Pellicani V, Caroli A, et al. Shift work sleep disorder and job stress in shift nurses: implications for preventive interventions. Med Lav 2020; 111(3): 195–202, doi: 10.23749/mdl.v111i3.9197.
37.
Lallukka T, Kaikkonen R, Härkänen T, et al. Sleep and sickness absence: a nationally representative register-based follow-up study. Sleep 2014; 37: 1413–1425, doi: 10.5665/sleep.3986.
38.
Veghari G, Sedaghat M, Joshghani H, et al. Obesity and risk of hypercholesterolemia in Iranian northern adults. ARYA Atheroscler 2013; 9(1): 2–6.
39.
Corica F, Corsonello A, Apolone G, et al. Construct validity of the Short Form-36 Health Survey and its relationship with BMI in obese outpatients. Obesity 2006; 14(8): 1429–1437, doi: 10.1038/oby.2006.162.
40.
Lee W, Kwon C, Rhee E, et al. The effect of body mass index and fasting glucose on the relationship between blood pressure and incident diabetes mellitus: a 5-year follow-up study. Hypertens Res 34(2011): 1093–1097, doi: https://doi.org/10.1038/hr.2011.89.
41.
Galen KA, van, Ter Horst KW, Serlie MJ, et al. Serotonin, food intake, and obesity. Obes Rev 2021; 22(7): e13210, doi: 10.1111/obr.13210.
42.
Howard R, Roth T, Drakeet CL. The effects of armodafinil on objective sleepiness and performance in a shift work dis-order sample unselected for objective sleepiness. J Clin Psychopharmacol 2014; 34(3): 369–373, doi: 10.1097/JCP.0000000000000136.
43.
Tkachenko V, Bagro T. Mental health and sleep disorders in obese patients, their relationship with clinical-pathogenetic changes in the body and impact on quality of life. Fam Med Eur Pract 2020; 4(102): 5–10, doi: 10.30841/2786-720X.4.2022.274617.
44.
Tkachenko V, Bagro T. Effectiveness of motivational counseling for lifestyle modification in obese patients using a patient-centered approach. Fam Med Eur Pract 2023; 1(103): 20–27, doi: 10.30841/2786-720X.1.2023.277475.
